ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on January 23, 2019, with the earliest event reported on that date. The filing details the approval of 2018 performance-based compensation for named executive officers and the execution of amended and restated employment agreements dated January 29, 2019.
Key Financial Metrics and Compensation
The filing does not provide consolidated financial statements, revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation adjustments and new contractual obligations.
| Executive Officer | 2019 Base Salary | 2018 Cash Bonus | Stock Options Granted | Exercise Price |
|---|---|---|---|---|
| Adam S. Grossman (CEO) | $536,000 | $215,205 | 400,000 | $3.22 |
| Dr. James Mond (CSO/CMO) | $415,000 | $117,325 | 200,000 | $3.22 |
| Brian Lenz (CFO) | $390,000 | $107,105 | 200,000 | $3.22 |
Notes:
- Cash bonuses reflect 73% achievement of 2018 corporate goals and are payable in late February 2019.
- Stock options vest over four years (25% at one year, remainder monthly).
- Dr. Mond's and Mr. Lenz's base salaries represent increases of approximately 3.3% and 6.3%, respectively, effective January 1, 2019.
Material Changes and Employment Agreements
On January 29, 2019, the Company entered into amended and restated employment agreements with its three named executive officers. Key terms include:
- Termination Provisions: Agreements allow termination by either party with or without notice. Severance is triggered by termination without "Cause," resignation for "Good Reason," or termination following a "Change of Control."
- Severance Packages:
- CEO: 12 months' base salary plus target bonus (18 months' salary plus 1.5x bonus if within 2 years of Change of Control).
- CSO/CFO: 9 months' base salary plus target bonus (12 months' salary plus 1x bonus if within 1 year of Change of Control).
- Accelerated Vesting: Full acceleration of stock options occurs upon termination without Cause or for Good Reason immediately preceding or within a specified window (2 years for CEO, 1 year for others) following a Change of Control.
- COBRA Reimbursement: The Company will reimburse health insurance premiums for 12 months (or 18 months for CEO in Change of Control scenarios) following qualifying terminations.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance, revenue outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential future cash outflows associated with the new severance obligations and the dilution from the 800,000 newly granted stock options.
Investor Verification Checklist
- Verify the Company's current cash position to assess the ability to fund the $439,635 in immediate cash bonuses and potential future severance obligations.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the impact of the 800,000 new stock options on the Company's fully diluted share count and potential dilution to existing shareholders.
- Assess the 73% achievement of 2018 corporate goals in the context of the Company's overall operational progress.